This week, StemCells announced the publication of clinical and preclinical data in Science Translational Medicine with implications for treating myelination disorders, including multiple sclerosis, cerebral palsy and spinal cord injury.
In the clinical study, all four patients with a rare disease, Pelizaeus-Merzbacher disease (PMD), demonstrated creation of myelin, which has never before been demonstrated. Three of the four patients showed modest gains in their neurological function, and the fourth remained stable. It is important to note that this Phase 1 study did not contain a control arm, so further studies must be conducted.
A preclinical study that demonstrated the production of myelin in an animal model of severe myelin deficiency was simultaneously published and provided the rationale for the PMD clinical trial and further supports the company’s approach for treating other myelination disorders.
Read more about the study and results in the article below from WebMD.
